Compression Stockings to Prevent Nerve Damage From Cancer Drug Infusions in Urothelial Carcinoma

Trial details

Who runs it

Sheng Zhang

Trial code

NCT07164950

Record updated

15 September 2025

Original description

This multicenter, prospective phase II clinical trial aims to evaluate the efficacy and safety of medical compression stockings in preventing peripheral neuropathy induced by antibody-drug conjugates (ADCs) containing monomethyl auristatin E (MMAE) in patients with advanced cancers, including urothelial carcinoma. Eligible participants will have no baseline ≥ grade 1 neuropathy and will be scheduled to receive MMAE-containing ADC therapy. A total of 58 patients will be enrolled and followed for 24 months. In this self-controlled design, the left foot will be fitted with a medical compression stocking while the right foot remains uncovered, starting 15 minutes before infusion and continuing until 15 minutes after infusion (total duration: 120 minutes). Peripheral neuropathy will be assessed before treatment, after cycle 3, within 1 week after treatment completion, and 1 month after completion, using CTCAE v5.0 and patient-reported questionnaires (QLQ-C30 and FACT-GOG-NTx). Toe temperature will be measured to assess local microcirculation changes. The study will also monitor compression-related adverse events. The results will provide evidence for preventive strategies to reduce ADC-induced peripheral neuropathy and improve patients' quality of life.Read full original descriptionShow less

A Multicenter, Prospective, Phase II Clinical Trial Investigating the Use of Compression Stockings to Prevent Peripheral Neuropathy Induced by Antibody-Drug Conjugates (ADCs) in Patients With Urothelial Carcinoma

This multicenter, prospective phase II clinical trial aims to evaluate the efficacy and safety of medical compression stockings in preventing peripheral neuropathy induced by antibody-drug conjugates (ADCs) containing monomethyl auristatin E (MMAE) in patients with advanced cancers, including urothelial carcinoma. Eligible participants will have no baseline ≥ grade 1 neuropathy and will be scheduled to receive MMAE-containing ADC therapy. A total of 58 patients will be enrolled and followed for 24 months. In this self-controlled design, the left foot will be fitted with a medical compression stocking while the right foot remains uncovered, starting 15 minutes before infusion and continuing until 15 minutes after infusion (total duration: 120 minutes). Peripheral neuropathy will be assessed before treatment, after cycle 3, within 1 week after treatment completion, and 1 month after completion, using CTCAE v5.0 and patient-reported questionnaires (QLQ-C30 and FACT-GOG-NTx). Toe temperature will be measured to assess local microcirculation changes. The study will also monitor compression-related adverse events. The results will provide evidence for preventive strategies to reduce ADC-induced peripheral neuropathy and improve patients' quality of life.

Inclusion: Age ≥ 18 years Histologically or cytologically confirmed advanced malignancy (including but not limited to urothelial carcinoma) eligible for MMAE-containing ADC therapy (e.g., EV, DV, BV); ECOG performance status 0-2; No baseline peripheral neuropathy ≥ Grade 1 (CTCAE v5.0); Stable tumor status without other neurotoxic drugs in the past 2 months; Adequate organ function (blood counts, liver and kidney function) per protocol; Expected survival ≥ 3 months; Ability and willingness to comply with study procedures and provide written informed consent.

Exclusion: Pre-existing peripheral neuropathy ≥ Grade 1 from prior platinum/taxane treatment; Known bleeding or coagulation disorders or receiving thrombolytic therapy; Severe diabetes or peripheral vascular disease; Neurological disorders causing nerve compression (e.g., carpal tunnel syndrome, radiculopathy); Severe psychiatric conditions (depression, bipolar disorder, substance abuse); Active uncontrolled infections requiring systemic antibiotics/antifungals/antivirals (≥ CTCAE Grade 2); Active hepatitis or significant liver dysfunction not meeting inclusion criteria; Renal failure requiring dialysis; Immunodeficiency or history of organ transplantation; Active tuberculosis or uncontrolled pleural/pericardial effusion/ascites; Hypersensitivity to monoclonal antibodies or study device components; Any other condition judged by the investigator to preclude safe participation; Poor compliance or inability to follow protocol; Severe nausea, headache, fatigue, or other debilitating symptoms; Participation in other clinical trials within 4 weeks.

ClinicalTrials.gov NCT07164950